$3.37 Million in Sales Expected for Viveve Medical Inc (VIVE) This Quarter

Share on StockTwits

Analysts forecast that Viveve Medical Inc (NASDAQ:VIVE) will post sales of $3.37 million for the current quarter, according to Zacks. Three analysts have made estimates for Viveve Medical’s earnings, with the highest sales estimate coming in at $4.15 million and the lowest estimate coming in at $2.90 million. Viveve Medical reported sales of $3.70 million in the same quarter last year, which would suggest a negative year over year growth rate of 8.9%. The business is expected to announce its next quarterly earnings report on Thursday, May 9th.

On average, analysts expect that Viveve Medical will report full-year sales of $19.48 million for the current financial year, with estimates ranging from $19.00 million to $20.05 million. For the next financial year, analysts expect that the business will report sales of $28.60 million, with estimates ranging from $24.65 million to $34.07 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Viveve Medical.

VIVE has been the subject of several analyst reports. Maxim Group restated a “buy” rating and issued a $6.00 target price on shares of Viveve Medical in a research report on Monday, February 11th. Mizuho restated a “buy” rating and issued a $4.00 target price on shares of Viveve Medical in a research report on Friday, March 15th. Finally, Craig Hallum set a $1.00 target price on shares of Viveve Medical and gave the company a “hold” rating in a research report on Friday, January 18th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $3.50.

Several institutional investors have recently made changes to their positions in VIVE. Geode Capital Management LLC lifted its position in shares of Viveve Medical by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock valued at $227,000 after acquiring an additional 25,975 shares during the period. Pennsylvania Trust Co lifted its position in shares of Viveve Medical by 212.3% during the 1st quarter. Pennsylvania Trust Co now owns 42,154 shares of the company’s stock valued at $7,681,000 after acquiring an additional 28,654 shares during the period. Sargent Investment Group LLC acquired a new position in shares of Viveve Medical during the 4th quarter valued at $32,000. Bank of New York Mellon Corp lifted its position in shares of Viveve Medical by 266.6% during the 4th quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock valued at $47,000 after acquiring an additional 32,888 shares during the period. Finally, Accredited Investors Inc. acquired a new position in shares of Viveve Medical during the 1st quarter valued at $31,000. 60.99% of the stock is currently owned by institutional investors.

Viveve Medical stock traded down $0.02 during midday trading on Friday, hitting $0.48. The company’s stock had a trading volume of 328,421 shares, compared to its average volume of 316,008. The stock has a market capitalization of $23.02 million, a price-to-earnings ratio of -0.30 and a beta of 0.70. The company has a quick ratio of 3.51, a current ratio of 3.89 and a debt-to-equity ratio of 6.21. Viveve Medical has a 1-year low of $0.47 and a 1-year high of $4.34.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Further Reading: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TD Securities Lowers Turquoise Hill Resources  Price Target to C$4.00
TD Securities Lowers Turquoise Hill Resources Price Target to C$4.00
San Miguel  Rating Lowered to Sell at Zacks Investment Research
San Miguel Rating Lowered to Sell at Zacks Investment Research
Activision Blizzard  Stock Price Down 6% After Insider Selling
Activision Blizzard Stock Price Down 6% After Insider Selling
Enquest Plc  Insider Buys £109,193 in Stock
Enquest Plc Insider Buys £109,193 in Stock
L Brands  to Release Quarterly Earnings on Wednesday
L Brands to Release Quarterly Earnings on Wednesday
TrueUSD Market Capitalization Tops $242.28 Million
TrueUSD Market Capitalization Tops $242.28 Million


© 2006-2019 Ticker Report